- Home
- MRCC vs IKT Comparison
MRCC vs IKT Comparison
Compare MRCC & IKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRCC
- IKT
- Stock Information
- Founded
- MRCC 2011
- IKT 2008
- Country
- MRCC United States
- IKT United States
- Employees
- MRCC N/A
- IKT N/A
- Industry
- MRCC Investment Managers
- IKT Biotechnology: Pharmaceutical Preparations
- Sector
- MRCC Finance
- IKT Health Care
- Exchange
- MRCC Nasdaq
- IKT Nasdaq
- Market Cap
- MRCC 174.8M
- IKT 159.2M
- IPO Year
- MRCC 2012
- IKT 2020
- Fundamental
- Price
- MRCC $8.23
- IKT $2.05
- Analyst Decision
- MRCC Strong Buy
- IKT Strong Buy
- Analyst Count
- MRCC 1
- IKT 2
- Target Price
- MRCC $9.00
- IKT $6.50
- AVG Volume (30 Days)
- MRCC 63.8K
- IKT 359.9K
- Earning Date
- MRCC 11-12-2024
- IKT 11-14-2024
- Dividend Yield
- MRCC 12.15%
- IKT N/A
- EPS Growth
- MRCC 298.01
- IKT N/A
- EPS
- MRCC 0.60
- IKT N/A
- Revenue
- MRCC $62,007,000.00
- IKT $1.00
- Revenue This Year
- MRCC N/A
- IKT N/A
- Revenue Next Year
- MRCC N/A
- IKT N/A
- P/E Ratio
- MRCC $13.71
- IKT N/A
- Revenue Growth
- MRCC N/A
- IKT N/A
- 52 Week Low
- MRCC $6.77
- IKT $0.80
- 52 Week High
- MRCC $8.41
- IKT $3.82
- Technical
- Relative Strength Index (RSI)
- MRCC 58.52
- IKT 42.19
- Support Level
- MRCC $7.97
- IKT $2.56
- Resistance Level
- MRCC $8.18
- IKT $3.69
- Average True Range (ATR)
- MRCC 0.15
- IKT 0.34
- MACD
- MRCC 0.03
- IKT -0.10
- Stochastic Oscillator
- MRCC 87.50
- IKT 5.75
About MRCC Monroe Capital Corporation
Monroe Capital Corp is a speciality finance company focused on providing financing to lower middle-market companies, in the U.S. and Canada. The company provides customized financing solutions focused on senior, unitranche, and junior secured debt and unsecured subordinated debt and equity, including equity co-investments in preferred and common stock and warrants.
About IKT Inhibikase Therapeutics Inc.
Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease ("PD"), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.